Medicalsystem Biotechnology Co., Ltd. (300439.SZ)
CNY 10.93
(1.3%)
CNY 10.93
(1.3%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 279.11 Million CNY | -21.51% |
| 2022 | 322.01 Million CNY | 9.46% |
| 2021 | 294.19 Million CNY | -36.24% |
| 2020 | 461.42 Million CNY | 12.35% |
| 2019 | 410.71 Million CNY | 20.19% |
| 2018 | 341.71 Million CNY | -1.14% |
| 2017 | 345.65 Million CNY | 70.02% |
| 2016 | 203.3 Million CNY | 15.41% |
| 2015 | 176.15 Million CNY | 6.9% |
| 2014 | 164.78 Million CNY | 31.75% |
| 2013 | 125.06 Million CNY | 17.62% |
| 2012 | 106.33 Million CNY | 60.75% |
| 2011 | 66.14 Million CNY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 85.09 Million CNY | 520.81% |
| 2024 Q3 | 63.04 Million CNY | -38.23% |
| 2024 Q2 | 102.07 Million CNY | 19.95% |
| 2023 Q4 | 13.7 Million CNY | -79.53% |
| 2023 FY | 252.75 Million CNY | -21.51% |
| 2023 Q1 | 76.31 Million CNY | 997.41% |
| 2023 Q3 | 66.96 Million CNY | -42.45% |
| 2023 Q2 | 116.37 Million CNY | 52.5% |
| 2022 FY | 322.01 Million CNY | 9.46% |
| 2022 Q2 | 90.23 Million CNY | 11.76% |
| 2022 Q4 | -8.5 Million CNY | -112.85% |
| 2022 Q1 | 80.74 Million CNY | 313.12% |
| 2022 Q3 | 66.16 Million CNY | -26.67% |
| 2021 Q3 | 50.73 Million CNY | -25.23% |
| 2021 FY | 294.19 Million CNY | -36.24% |
| 2021 Q1 | 81.55 Million CNY | 14725.07% |
| 2021 Q2 | 67.85 Million CNY | -16.8% |
| 2021 Q4 | 19.54 Million CNY | -61.48% |
| 2020 Q4 | -557.66 Thousand CNY | -100.67% |
| 2020 Q3 | 83.52 Million CNY | 9.25% |
| 2020 FY | 461.42 Million CNY | 12.35% |
| 2020 Q1 | 13.5 Million CNY | 101.66% |
| 2020 Q2 | 76.44 Million CNY | 465.92% |
| 2019 Q3 | 97.83 Million CNY | 12.95% |
| 2019 FY | 410.71 Million CNY | 20.19% |
| 2019 Q4 | -812.17 Million CNY | -930.12% |
| 2019 Q2 | 86.62 Million CNY | -15.31% |
| 2019 Q1 | 102.28 Million CNY | 50.48% |
| 2018 Q1 | 78.46 Million CNY | -44.83% |
| 2018 Q4 | 67.96 Million CNY | -20.41% |
| 2018 Q2 | 109.88 Million CNY | 40.04% |
| 2018 Q3 | 85.39 Million CNY | -22.28% |
| 2018 FY | 341.71 Million CNY | -1.14% |
| 2017 Q3 | 75.82 Million CNY | 12.66% |
| 2017 FY | 345.65 Million CNY | 70.02% |
| 2017 Q1 | 60.29 Million CNY | 99.78% |
| 2017 Q2 | 67.3 Million CNY | 11.62% |
| 2017 Q4 | 142.22 Million CNY | 87.57% |
| 2016 Q3 | 71.95 Million CNY | 24.22% |
| 2016 FY | 203.3 Million CNY | 15.41% |
| 2016 Q2 | 57.92 Million CNY | 33.95% |
| 2016 Q1 | 43.24 Million CNY | -2.24% |
| 2016 Q4 | 30.18 Million CNY | -58.05% |
| 2015 Q1 | 40.72 Million CNY | 2.96% |
| 2015 Q4 | 44.23 Million CNY | -17.04% |
| 2015 Q3 | 53.31 Million CNY | 40.75% |
| 2015 Q2 | 37.88 Million CNY | -6.99% |
| 2015 FY | 176.15 Million CNY | 6.9% |
| 2014 FY | 164.78 Million CNY | 31.75% |
| 2014 Q3 | 49.34 Million CNY | 23.52% |
| 2014 Q4 | 39.55 Million CNY | -19.85% |
| 2014 Q1 | 35.92 Million CNY | 0.0% |
| 2014 Q2 | 39.95 Million CNY | 11.2% |
| 2013 FY | 125.06 Million CNY | 17.62% |
| 2012 FY | 106.33 Million CNY | 60.75% |
| 2011 FY | 66.14 Million CNY | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Dian Diagnostics Group Co.,Ltd. | 998.13 Million CNY | 72.036% |
| Hangzhou Tigermed Consulting Co., Ltd. | 2.48 Billion CNY | 88.777% |
| Dirui Industrial Co.,Ltd. | 296.87 Million CNY | 5.981% |
| Beijing Strong Biotechnologies, Inc. | 593.87 Million CNY | 53.001% |
| Maccura Biotechnology Co.Ltd | 331.14 Million CNY | 15.712% |
| Guangzhou Wondfo Biotech Co.,Ltd | 549.13 Million CNY | 49.172% |
| Guangdong Hybribio Biotech Co.,Ltd. | 42.59 Million CNY | -555.208% |
| BGI Genomics Co., Ltd. | 150.64 Million CNY | -85.276% |
| Amoy Diagnostics Co., Ltd. | 301.24 Million CNY | 7.346% |
| Shanghai Labway Clinical Laboratory Co., Ltd. | -135.82 Million CNY | 305.499% |